Exocrine pancreatic insufficiency (EPI) is an inability of proper digestion of food owing to insufficient levels of digestive enzymes from pancreas. EPI is commonly found in humans affected with Shwachman-Diamond Syndrome and cystic fibrosis. EPI is triggered by the progressive loss of pancreatic cells, which generates the digestive enzymes. EPI disturbs the normal growth, life expectancy and immune response. Diarrhoea, Steatorrhea, fatigue and weight loss are the key symptoms of EPI.
Key factors responsible for growth of this market involve, increasing global incidences of exocrine pancreatic insufficiency, demands of advanced therapeutics and presence of significant number of pipeline drugs. Recent trends in therapeutics include: lipase treatment in dietetic patients, optimizing the chymotrypsin and trypsin levels. However, in the painful chronic exocrine pancreatitis, high dose protease are estimated to be beneficial. Individual pancreatic replacement therapy along with pancreatin medication is advised to the patient in severe cases. According to the research conducted by Robbins basic pathology, exocrine pancreatic insufficiency was observed to occur in the 85% to 90% of patients with cystic fibrosis in 2013. Pancreatic replacement therapy in EPI is an extensively accepted mode of treatment and aids in minimizing the malabsorption and related malnutrition. Primarily, these pancreatic digestive enzymes include lipase for the fat digestion, protease for the protein digestion, and amylase for the starch digestion in the body. Following pancreatic enzyme products (PEPs) were approved by USFDA for the treatment of EPI: Zenpep and Creon in 2009, Viokace and Ultresa in 2012, Pancreaze in 2010, and Pertzye in 2012. In developed regions, rising geriatric population, minimum death rates and are the key factors driving the incidences of EPI. Enhanced demand for the advanced therapeutics and rising percentage geriatric population affected population are other factors responsible for the growth of this market. Substantial number of new chemical entities (NCEs) in various phases of clinical trials that will emerge in the global market is the main opportunity in the market. However, the lack of technological reach and insufficient advanced treatments are the key restraints of exocrine pancreatic insufficiency market in developing regions.
Geographically, North America and Europe will lead the market owing to high percentage of geriatric population, significant number of research and drug development activities. However, Asia-Pacific region is expected to show rapid growth owing to growth of pharmaceutical and healthcare industry and improving purchasing power of the service providers in this region. Rapidly emerging economies in region such as India, China, and more disease prevalence will drive the growth of exocrine pancreatic insufficiency market. Some of the key players operated in the exocrine pancreatic insufficiency market are Axcan, Aptalis Pharma, Inc., Eli Lilly & Co., Cilian AG, Nordmark Arzneimittel GmbH & Co. KG and Laboratoires Mayoly Spindler.
KEY MARKET SEGMENTS
Exocrine Pancreatic Insufficiency market is segmented by the mode of disease management, diagnostic tests and geography.
MARKET BY DISEASE MANAGEMENT
MARKET BY DIAGNOSIS
MARKET BY GEOGRAPHY
SIMILAR MARKET STUDIES
DNA sequencing Market by Product (Consumable, Instrument, and Service) Application (Biomarkers and Cancer, Diagnostics, Reproductive Health, Personalized Medicine, Forensics, and Other Applications), Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Pyrosequencing, Single Molecule Real-Time Sequencing, Chain Termination Sequencing, and Nanopore Sequencing), and End User (Academic & Government Research Institutes, Pharmaceutical Companies, Biotechnology Companies, and Hospitals & Clinics): Global Opportunity Analysis and Industry Forecast, 2017-2023
DNA sequencing is a molecular technique, which help to determine the nucleotide sequence of DNA (deoxyribonucleic acid), which is the most fundamental level of knowledge of a gene or genome. The global DNA sequencing market accounted for $5,156 million in 2016, and is anticipated to reach $18,284 million by 2023, ...
May 2017 | $5370 | View Details >>
Nerve Repair and Regeneration Market by Surgery [Direct Neuropathy by Type (Epineural Repair, Perineural Repair, and Group Fascicular Repair), Nerve Grafting by Type (Autografts, Allografts, and Xenografts), Neuromodulation Surgery (External and Internal), and Stem Cell Therapy] and Product [Biomaterial by Type (Nerve Conduits, Nerve Protectors, Nerve Wraps, and Nerve Connectors) and Neuromodulation Surgery Devices by Type (External by Type (Transcutaneous Electrical Nerve Stimulation and Transcranial Magnetic Stimulation) and Internal by Type (Spinal Cord Stimulation, Deep Brain Stimulation, Sacral Nerve Stimulation, Vagus Nerve Stimulation, and Others)]: Global Opportunity Analysis and Industry Forecast, 2017-2023
Patients with serious nervous system injuries or strokes often require lifelong assistance, which burdens patients, their families, and society. Innovative, paradigm shifting strategies are required to develop treatments for neurological injury. Early diagnosis and treatment can prevent complications and permanent injuries. The techniques of nerve repair and regeneration aid to cure the disorders such Alzheimerâ€™s disease, Parkinson disease, and other neurological disorders.
May 2017 | $5370 | View Details >>
Malaysia Intravenous Immunoglobulin (IVIG) Market by Product Types (IgG, IgA, IgM, IgE and IgD), Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Immune Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-BarrÃ© Syndrome, Kawasaki Disease, Secondary Immune Deficiency, And Other Applications), Mode of Delivery (Intravenous, Intramuscular, Subcutaneous), and Concentration (5%, 10% and Other Concentration): Opportunity Analysis and Industry Forecast, 2014-2022
Intravenous immunoglobulin (IVIG) is a blood/plasma product, which is prepared from the serum of multiple of donors, used to treat patients with antibody deficiency. The isolated plasma product is clinically treated and purified to Ig, which further facilitates the treatment. IVIG is applicable in various fields such as hematology, immunology, neurology, dermatology, nephrology, ophthalmology, and rheumatology.
May 2017 | $2850 | View Details >>
UPCOMING MARKET RESEARCH REPORTS
2017 © Copyright Big Market Research